Myocardial perfusion reserve after a PET-driven revascularization procedure: A strong prognostic factor

Journal of Nuclear Medicine

Volumn 52, Issue 6, 2011, Pages 873-879

  Slart, Riemer H J A ^a   Zeebregts, Clark J ^a   Hillege, Hans L ^a   De Sutter, Johan ^b   Dierckx, Rudi A J O ^a   Van Veldhuisen, Dirk J ^a   Zijlstra, Felix ^a   Tio, René A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b AZ Maria Middelares ^*  (Belgium)

Author keywords

Coronary artery disease; Intervention; Long term outcome; LV function; Myocardial perfusion reserve; Positron emission tomography

Indexed keywords

AMMONIA N 13; FLUORODEOXYGLUCOSE F 18;

AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE PERFUSION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVASCULARIZATION;

AGED; AMMONIA; CAPILLARIES; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; DIPYRIDAMOLE; ENDPOINT DETERMINATION; EXERCISE TEST; FEMALE; FLUORODEOXYGLUCOSE F18; HEART; HEMODYNAMICS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; MYOCARDIAL STUNNING; PERFUSION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RECOVERY OF FUNCTION; SURGERY, COMPUTER-ASSISTED; SURVIVAL ANALYSIS; VASODILATOR AGENTS;

EID: 79958132074     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.084954     Document Type: Article

References (34)

1. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151-1158. (Pubitemid 34267418)
2. Beanlands RS, Ruddy TD, deKemp RA, et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol. 2002;40:1735-1743. (Pubitemid 35341950)
3. Siebelink HM, Blanksma PK, Crijns HJ, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol. 2001;37:81-88. (Pubitemid 32051722)
4. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002-2012. (Pubitemid 350054917)
5. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349:1027-1035. (Pubitemid 37087617)
6. Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation. 2002;105:186-193. (Pubitemid 34084317)
7. Tio RA, Dabeshlim A, Siebelink HM, et al. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med. 2009;50:214-219.
8. 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol. 2009;54:150-156.
9. Bax JJ, Visser FC, Elhendy A, et al. Prediction of improvement of regional left ventricular function after revascularization using different perfusion-metabolism criteria. J Nucl Med. 1999;40:1866-1873. (Pubitemid 29523581)
10. Blanksma PK, Willemsen ATM, Meeder JG, et al. Quantitative myocardial mapping of perfusion and metabolism using parametric polar map displays in cardiac PET. J Nucl Med. 1995;36:153-158.
11. Knuuti MJ, Yki-Jarvinen H, Voipio-Pulkki LM, et al. Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. J Nucl Med. 1994;35:989-998. (Pubitemid 24168127)
12. Knuuti MJ, Nuutila P, Ruotsalainen U, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med. 1992;33:1255-1262.
13. Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol. 1990;15:1032-1042. (Pubitemid 20104558)
14. Gambhir SS, Schwaiger M, Huang SC, et al. Simple noninvasive quantification method for measuring myocardial glucose-utilization in humans employing positron emission tomography and F-18 deoxyglucose. J Nucl Med. 1989;30:359-366. (Pubitemid 19077326)
15. Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol. 2002;40:1567-1572. (Pubitemid 35253633)
16. Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989;117:211-221.
17. Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol. 1997;30:1693-1700. (Pubitemid 27521251)
18. Tamaki N, Kawamoto M, Tadamura E, et al. Prediction of reversible ischemia after revascularization: perfusion and metabolic studies with positron emission tomography. Circulation. 1995;91:1697-1705.
19. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314:884-888. (Pubitemid 16126116)
20. Bax JJ, Cornel JH, Visser FC, et al. Prediction of recovery of myocardial dysfunction after revascularization: comparison of fluorine-18 fluorodeoxyglucose/ thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. J Am Coll Cardiol. 1996;28:558-564.
21. Schinkel AF, Bax JJ, Poldermans D. Clinical assessment of myocardial hibernation. Heart. 2005;91:111-117. (Pubitemid 39665014)
22. Al Saadi N, Nagel E, Gross M, et al. Improvement of myocardial perfusion reserve early after coronary intervention: assessment with cardiac magnetic resonance imaging. J Am Coll Cardiol. 2000;36:1557-1564.
23. Selvanayagam JB, Cheng AS, Jerosch-Herold M, et al. Effect of distal embolization on myocardial perfusion reserve after percutaneous coronary intervention: a quantitative magnetic resonance perfusion study. Circulation. 2007;116:1458-1464. (Pubitemid 47480636)
24. Guethlin M, Kasel AM, Coppenrath K, Ziegler S, Delius W, Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation. 1999;99:475-481. (Pubitemid 29061861)
25. Tio RA, Slart RH, de Boer RA, et al. Reduced regional myocardial perfusion reserve is associated with impaired contractile performance in idiopathic dilated cardiomyopathy. Neth Heart J. 2009;17:470-474.
26. van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2000;35:19-28.
27. de Boer RA, Pinto YM, van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation. 2003;10:113-126. (Pubitemid 39004240)
28. van Veldhuisen DJ, van den Heuvel AF, Blanksma PK, Crijns HJ. Ischemia and left ventricular dysfunction: a reciprocal relation? J Cardiovasc Pharmacol. 1998;32(suppl 1):S46-S51.
29. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933-989.
30. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-2515.
31. Holmes DR Jr, Kim LJ, Brooks MM, et al. The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation. J Thorac Cardiovasc Surg. 2007;134:38-46.
32. Gould KL. Not all randomized trials are equal. J Am Coll Cardiol. 2007;50:2013-2015.
33. Schindler TH, Cadenas J, Facta AD, et al. Improvement in coronary endothelial function is independently associated with a slowed progression of coronary artery calcification in type 2 diabetes mellitus. Eur Heart J. 2009;30:3064-3073.
34. Schindler TH, Campisi R, Dorsey D, et al. Effect of hormone replacement therapy on vasomotor function of the coronary microcirculation in post-menopausal women with medically treated cardiovascular risk factors. Eur Heart J. 2009;30:978-986.